Condition (MeSH)
Primary Ovarian Insufficiency
ClinicalTrials.gov lists 179 trials for Primary Ovarian Insufficiency or a narrower condition beneath it. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) has the most among industry and government lead sponsors, with 11.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
179 of the 179 trials are tagged with Primary Ovarian Insufficiency itself; the rest are tagged with a narrower condition beneath it.
When did Primary Ovarian Insufficiency trials start? (29)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 15
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 15 |
| 2025 | 14 |
| 2024 | 9 |
| 2023 | 15 |
| 2022 | 11 |
| 2021 | 12 |
| 2020 | 8 |
| 2019 | 12 |
| 2018 | 12 |
| 2017 | 8 |
Showing 10 of 29 earlier years.
Forecast of the full-year count, planned starts included, not rows of this table: about 19 trials starting in 2026 and about 16 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Prediction, not a registry value: median of 36 months from start to primary completion across 16 trials still running at the 2026-10-09 snapshot; registered median of 32 months across 65 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Primary Ovarian Insufficiency trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 16 |
| Phase 1/2 | 23 |
| Phase 2 | 10 |
| Phase 2/3 | 3 |
| Phase 3 | 7 |
| Phase 4 | 10 |
| Not applicable | 49 |
| Observational | 61 |
How many Primary Ovarian Insufficiency trials are recruiting? (9)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 16 |
| Recruiting | 22 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 10 |
| Completed | 56 |
Showing 5 of 9 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Primary Ovarian Insufficiency trials? (2)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 11 |
| Chinese Academy of Sciences | 3 |
Which drugs are being tested for Primary Ovarian Insufficiency? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Estradiol | 3 |
| Lisdexamfetamine Dimesylate | 3 |
Interventions as named in the registry (13)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| [PRP] platelet rich plasma | 7 |
| r-hCG | 3 |
| Hormone Replacement Therapy | 3 |
| Dehydroepiandrosterone | 3 |
| Filgrastime (G-CSF) | 2 |
Showing 5 of 13 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Primary Ovarian Insufficiency trials report? (3)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| DVT | 1 | 1 |
| Diabetic ketoacidosis (DKA) hospitalization | 1 | 1 |
| Suicidality | 1 | 1 |
Which publications cover Primary Ovarian Insufficiency? (232)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Platelet-Rich Plasma and Electrochemical Biosensors: A Novel Approach to Ovarian Function Evaluation and Diagnostics. | International journal of molecular sciences | 2025 | Yes |
| Association of LHCGR rs2293275 genotype with ovarian aging in Chinese women: a multicenter population-based study. | Reproductive biology and endocrinology : RB&E | 2025 | Yes |
| Efficacy and safety of autologous adipose tissue-derived stromal vascular fraction in patients with premature ovarian insufficiency: protocol for a single-centre randomised controlled trial. | BMJ open | 2025 | Yes |
| Drug-free in vitro activation of ovarian follicles and fresh tissue autotransplantation in patients with poor ovarian response and premature ovarian insufficiency. | F&S science | 2025 | Yes |
| Impact of bilateral intraovarian platelet-rich plasma in women with poor ovarian response or primary ovarian insufficiency: a retrospective study. | Fertility and sterility | 2025 | Yes |
Showing 5 of 232 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.